Use of cenobamate for the treatment of focal epilepsy: an Italian expert opinion paper.

2023-01-20

Villani, Flavio

Cianci, Vittoria

Di Bonaventura, Carlo

Di Gennaro, Giancarlo

Galimberti, Carlo Andrea

Guerrini, Renzo

La Neve, Angela

Mecarelli, Oriano

Pietrafusa, Nicola

Specchio, Nicola

Vigevano, Federico

Perucca, Emilio

Cenobamate

drug resistance

epilepsy

focal seizures

Journal Article

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0002-7272-7079

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

10.1080/14737175.2023.2171291

Cenobamate is a new antiseizure medication (ASM) recently introduced in the USA for the treatment of adults with focal-onset seizures. In March 2021, the European Commission authorized its use for the adjunctive treatment of focal-onset seizures with or without secondary generalization (focal seizures with or without progression to bilateral tonic-clonic seizures, according to current ILAE terminology) in adults with epilepsy not adequately controlled despite the treatment with at least two ASMs.

link

Expert Review of Neurotherapeutics 2023

Expert Review of Neurotherapeutics

1744-8360